LifeCapital Initiates Coverage Of NeoStem With Strong Buy

LifeCapital has initiated coverage of NeoStem NBS with a strong buy rating and a $3.75 price target. NeoStem is a biotechnology company in the autologous adult stem cell space. R&D efforts are ongoing in the United States, especially with their bone marrow-derived adult stem cell technology called VSEL (Very Smal Embryonic Like). NBS is also commercializing adult stem cell therapies in China with indications such as orthopedics, wellness, cosmetic, and anti-aging. NBS is also a leading provider of adult stem cell collection, processing, and storage services, called their "Bio-Insurance" program in the U.S and China for those with a family history of serious disease or at a high risk for wounds and trauma. LifeCapital believes the recent weakness in the stem cell sector represents an opportunity for investors in two future high-growth areas, stem cells therapeutics, and the Chinese healthcare market. NBS closed Friday at $1.73